Ginkgo Bioworks Holdings Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
DNA New York 8731 https://investors.ginkgobioworks.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks Announces Participation in Cowen's 43rd Annual Health Care Conference - Mar 2nd, 2023 12:00 pm
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results - Mar 1st, 2023 9:01 pm
Cronos Group Reports 2022 Fourth Quarter and Full-Year Results - Feb 28th, 2023 12:30 pm
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2022 Results Presentation - Feb 22nd, 2023 12:00 pm
Zymtronix and Ginkgo Bioworks Announce Partnership to Produce Enzymes for the Industrialization of Cell-Free Biomanufacturing - Feb 16th, 2023 12:00 pm
Ginkgo Bioworks Announces Pathogen Monitoring Program at Kigali International Airport - Feb 15th, 2023 12:00 pm
Bioweg and Ginkgo Bioworks Announce Partnership to Develop Cost Effective and Efficacious Bio-Based Materials to Reduce the Use of Microplastic Pollutants - Feb 6th, 2023 9:00 am
NAMUH and Ginkgo Bioworks Announce Partnership to Produce Multiple Infant Nutrition Products - Jan 18th, 2023 12:00 pm
Ginkgo Bioworks and XpresCheck Expand CDC’s Traveler-Based Genomic Surveillance Program to Detect Influenza Variants - Jan 17th, 2023 1:00 pm
Ginkgo Bioworks and the Public Health Center of the Ukraine Ministry of Health Announce Collaboration to Implement Biosecurity Capabilities in Ukraine - Jan 17th, 2023 12:00 pm
Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review - Jan 11th, 2023 12:00 pm
Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology - Jan 9th, 2023 12:00 pm
Ginkgo Bioworks Expands Its R&D Facilities, Opens Bioworks7 to Conduct Mammalian Screening at Scale, Widening Capabilities for Biopharma Partners - Jan 6th, 2023 12:00 pm
Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics - Jan 5th, 2023 12:00 pm
Ginkgo Bioworks Announces Participation in the 41st Annual J.P. Morgan Healthcare Conference - Jan 4th, 2023 12:00 pm
Boeing’s Delays Could Give Airbus’s A380 an Active Retirement - Jan 3rd, 2023 11:30 am
Ginkgo Bioworks and the Ministry of Health of the Republic of Botswana Announce Plans to Develop and Implement New Biosecurity Capabilities in Botswana - Dec 20th, 2022 12:00 pm
Ginkgo Bioworks Launches Ginkgo Enzyme Services, Enabling Applications across Pharmaceuticals and Diagnostics, Food and Agriculture, and Beyond - Dec 8th, 2022 12:00 pm
Ginkgo Bioworks Provides Compensation Information Related to Recent Acquisitions - Dec 2nd, 2022 12:00 pm